Jasmin Hundal/X
Apr 20, 2025, 09:09
Jasmin Hundal: Metabolic syndrome is not just a comorbidity but a modifier of breast cancer outcomes
Jasmin Hundal, Hematology Oncology Fellow at Cleveland Clinic, shared a post on LinkedIn:
“Metabolic Syndrome: A Modifier of Breast Cancer Outcomes—Not Just a Comorbidity
Metabolic syndrome, marked by insulin resistance, inflammation, and dyslipidemia, drives molecular changes that fuel breast cancer progression.
- Elevated IGF-1 activates the PI3K/Akt/mTOR and Ras/Raf/MEK/ERK pathways, promoting proliferation.
- Chronic inflammation through IL-6, IL-8, TNF-α activates JAK2/STAT3 and NF-κB, encouraging immune evasion and resistance.
- Dysregulated lipids and reduced SHBG increase estrogen bioavailability, further stimulating ERα/STAT3 signaling in hormone receptor–positive tumors.
These pathways reflect how metabolic dysfunction impact the tumor microenvironment and alters therapeutic response.
So how do we move forward?
As we design future clinical trials, it’s time to:
- Stratify patients by metabolic phenotype, not just BMI
- Integrate biomarkers of inflammation, insulin resistance, and lipid metabolism
- Explore combination therapies targeting both tumor and metabolic drivers
- Include lifestyle intervention arms that measure true metabolic impact
Could targeting metabolic dysfunction be the missing piece in reducing recurrence and impacting quality of life of our patients?”
More posts featuring Jasmin Hundal.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 20, 2025, 12:10
Apr 20, 2025, 11:55
Apr 20, 2025, 11:55
Apr 20, 2025, 11:51